Clinical Trials

October 29, 2024

Explore iadademstat for AML treatment in Oryzon Genomics' latest clinical trials with promising results.

October 22, 2024

What is RVU120, a new medicine in clinical trials, and how may it help reduce signs/symptoms of AML, MDS, and myelofibrosis?

October 09, 2024

Explore the AMpLify trial testing CRISPR-edited CAR-T therapy CB-012 for relapsed/refractory AML, now recruiting patients for Phase 1.

October 01, 2024

Understanding CAR T-Cell Therapy and the Armored CAR T-Cell Trial

September 30, 2024

Learn about clinical trials to open the door to accessing innovative cancer treatments.

September 16, 2024

Promising new off-the-shelf CAR NK cell therapy, SENTI-202, offers hope for relapsed/refractory AML & MDS. Learn about eligibility and trial locations.

September 06, 2024

Learn how BTK degrader BGB-16673 can aid in managing CLL/SLL if you've previously taken BTK inhibitors and venetoclax.

August 23, 2024

Learn how zanubrutinib and venetoclax helped high-risk CLL patients with del(17p)/TP53 mutation as their first treatment from the SEQUOIA study.

July 17, 2024

Learn about cem-cel, a CAR T-cell therapy made from donor T-cells that may decrease T-cell exhaustion and is more quickly available than liso-cel (Breyanzi).

July 12, 2024

AML specialist Harry Erba, MD, PhD, shared insight about a new treatment decision-making model for AML and MDS patients called myeloMATCH.